nach oben

International Journal of Diabetes in Developing Countries

Erschienen in:

16.06.2020 | Letter to the Editor

SGLT2 inhibitor/GLP-1 receptor agonists as first step monotherapy—evidence and implications

verfasst von: Anil Pareek, Ravi T. Mehta, Shruti Dharmadhikari

Erschienen in: International Journal of Diabetes in Developing Countries | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Excerpt

Dear Editor, …

Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2019:ehz486. https://doi.org/10.1093/eurheartj/ehz486.

Eurich DT, McAlister FA. Wrongfully accused: metformin use in heart failure. Expert Rev Cardiovasc Ther. 2011 Feb;9(2):147–50.CrossRef

Aguilar D, Chan W, Bozkurt B, Ramasubbu K, Deswal A. Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail. 2011 Jan;4(1):53–8.CrossRef

Roumie CL, Chipman J, Min JY, Hackstadt AJ, Hung AM, Greevy RA Jr, et al. Association of treatment with metformin vs sulfonylurea with major adverse cardiovascular events among patients with diabetes and reduced kidney function. JAMA. 2019 Sep;19:1–11. https://doi.org/10.1001/jama.2019.13206.CrossRef

Chawla R, Madhu SV, Makkar BM, Ghosh S, Saboo B, Kalra S. RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020. IJEM. 2020;24(1):1–122.PubMed

Lavalle-González FJ, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56(12):2582–92. https://doi.org/10.1007/s00125-013-3039-1.CrossRefPubMedPubMedCentral

Titel: SGLT2 inhibitor/GLP-1 receptor agonists as first step monotherapy—evidence and implications
verfasst von: Anil Pareek
Ravi T. Mehta
Shruti Dharmadhikari
Publikationsdatum: 16.06.2020
Verlag: Springer India
Erschienen in: International Journal of Diabetes in Developing Countries / Ausgabe 4/2020
Print ISSN: 0973-3930
Elektronische ISSN: 1998-3832
DOI: https://doi.org/10.1007/s13410-020-00833-4

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

SGLT2 inhibitor/GLP-1 receptor agonists as first step monotherapy—evidence and implications

Excerpt

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2020

Inflammatory response and timeline of chronic complications in patients with type 1 and 2 diabetes mellitus

A case-control study of mental health status of diabetic patients seen in Calabar, Nigeria

Effect of liraglutide on epicardial adipose tissue thickness with echocardiography in patients with obese type 2 diabetes mellitus

The effect of liraglutide on nonalcoholic fatty liver disease in type 2 diabetes mellitus

The impact of limited and strategic blood glucose monitoring on metabolic control in a type 1 diabetes clinic in Central India

A diabetes perception study among rural and urban individuals of West Bengal, India: are we ready for the pandemic?